Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO. Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| HBIO | HARVARD BIOSCIENCE INC | 2026-04-02 16:00:11 | 5.29 | 0.09 | 1.73 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HBIO | 0001123494 | HARVARD BIOSCIENCE INC | US4169061052 | 549300VLGB1D47GGC642 | 043306140 | Nasdaq | 3826 | Laboratory Analytical Instruments | 1231 | DE | 84 OCTOBER HILL RD | HOLLISTON | MA | 01746 | UNITED STATES | US | 5088938999 | 84 OCTOBER HILL ROAD, HOLLISTON, MA, 01746 | 84 OCTOBER HILL RD, HOLLISTON, MA, 01746 | — | — | 1901 | — | — | http://www.harvardbioscience.com/ | 18,200,000 | 44,719,894 | 44,719,894 | Harvard Bioscience is a global developer, manufacturer and marketer of life sciences equipment to support research and drug discovery. It is traded on NASDAQ under the stock symbol HBIO. Headquartered in Holliston, Massachusetts, United States, the company's brands include: Biochrom, BTX, CMA, Data Sciences International (DSI), Harvard Apparatus, HEKA, Hugo Sachs Elektronik, KD Scientific, Multi Channel Systems (MCS), Panlab, and Warner Instruments. The company has approximately 355 employees, with 216 of those in the USA, and its principal manufacturing facilities are in New Brighton, Minnesota, Holliston, Massachusetts, Reutlingen, Germany, Barcelona, Spain, and March, Germany. | 2026-04-02 20:09:46 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 18,200,000 | -97,000,000 | -84.2014 | 44,719,894 | 645,419 | 1.4644 |
| 2024 | 115,200,000 | -104,200,000 | -47.4932 | 44,074,475 | 675,184 | 1.5557 |
| 2023 | 219,400,000 | 77,600,000 | 54.725 | 43,399,291 | 1,209,248 | 2.8662 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| James W. Green | Chief Executive Officer, Chairman, President | 2024 | 513,431 | 0 | 1,800,000 | — | — | 2,336,576 |
| Jennifer Cote | Chief Financial Officer, Treasurer | 2024 | 293,654 | 0 | 300,000 | — | — | 602,601 |
| James W. Green | Chief Executive Officer, Chairman, President | 2023 | 585,625 | 0 | 1,772,760 | — | — | 2,392,240 |
| Jennifer Cote | Chief Financial Officer, Treasurer | 2023 | 285,789 | 67,500 | 210,000 | — | — | 571,272 |
| Michael A. Rossi | Chief Financial Officer | 2022 | 340,000 | — | 340,000 | 0 | 2,746 | 682,746 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 339 |
| 2024 | 355 |
| 2023 | 416 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 86,550,000 | 94,135,000 | 112,250,000 |
| Cost Of Revenue | 36,640,000 | 39,369,000 | 46,179,000 |
| Gross Profit | 49,910,000 | 54,766,000 | 66,071,000 |
| Research And Development Expenses | 8,825,000 | 10,406,000 | 11,764,000 |
| General And Administrative Expenses | 17,742,000 | 21,493,000 | 22,780,000 |
| Operating Expenses | 98,490,000 | 60,977,000 | 64,177,000 |
| Operating Income | -48,580,000 | -6,211,000 | 1,894,000 |
| Net Income | -56,700,000 | -12,405,000 | -3,415,000 |
| Earnings Per Share Basic | -1.28 | -0.28 | -0.08 |
| Earnings Per Share Diluted | -1.28 | -0.28 | -0.08 |
| Weighted Average Shares Outstanding Basic | 44,391,000 | 43,538,000 | 42,420,000 |
| Weighted Average Shares Outstanding Diluted | 44,391,000 | 43,538,000 | 42,420,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 8,614,000 | 4,108,000 | 4,283,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 16,043,000 | 14,866,000 | 16,099,000 |
| Inventories | 20,805,000 | 23,245,000 | 24,716,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 2,763,000 | 2,898,000 | 3,940,000 |
| Total Assets Current | 48,225,000 | 45,117,000 | 49,038,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 4,787,000 | 5,106,000 | 3,981,000 |
| Other Assets Non Current | 2,689,000 | 2,833,000 | 6,473,000 |
| Total Assets Non Current | 19,379,000 | 22,175,000 | 24,583,000 |
| Total Assets | 80,071,000 | 126,644,000 | 137,366,000 |
| Accounts Payable | 3,652,000 | 4,787,000 | 5,554,000 |
| Deferred Revenue | 3,447,000 | 3,806,000 | 4,508,000 |
| Short Term Debt | 0 | 37,350,000 | 6,139,000 |
| Other Liabilities Current | 14,861,000 | 9,409,000 | 9,205,000 |
| Total Liabilities Current | 21,960,000 | 54,958,000 | 26,542,000 |
| Long Term Debt | 35,870,000 | 36,956,000 | 36,563,000 |
| Other Liabilities Non Current | 1,308,000 | 1,255,000 | 1,476,000 |
| Total Liabilities Non Current | 44,377,000 | 8,346,000 | 37,750,000 |
| Total Liabilities | 66,337,000 | 63,304,000 | 64,292,000 |
| Common Stock | 447,000 | 441,000 | 434,000 |
| Retained Earnings | -214,710,000 | -158,010,000 | -145,605,000 |
| Accumulated Other Comprehensive Income | -11,672,000 | -15,670,000 | -14,190,000 |
| Total Shareholders Equity | 13,734,000 | 63,340,000 | 73,074,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,743,000 | 1,727,000 | 1,473,000 |
| Share Based Compensation Expense | 1,855,000 | 4,340,000 | 5,000,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 934,000 | -974,000 | -810,000 |
| Change In Inventories | -2,947,000 | 64,000 | -1,524,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 2,300,000 | -1,785,000 | 555,000 |
| Change In Other Liabilities | — | — | -1,078,000 |
| Cash From Operating Activities | 6,729,000 | 1,440,000 | 14,028,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 1,258,000 | 2,644,000 | 1,788,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -1,863,000 | -1,344,000 | -1,799,000 |
| Tax Withholding For Share Based Compensation | 156,000 | 577,000 | 2,523,000 |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 40,000,000 | — | — |
| Repayment Of Long Term Debt | 24,700,000 | 6,023,000 | 4,091,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | -1,291,000 | -131,000 | -12,134,000 |
| Change In Cash | 4,506,000 | -175,000 | -225,000 |
| Cash At End Of Period | 8,614,000 | 4,108,000 | 4,283,000 |
| Income Taxes Paid | -98,000 | -159,000 | 207,000 |
| Interest Paid | 3,595,000 | 3,235,000 | 3,795,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -1.28 | -0.28 | -0.08 |
| Price To Earnings Ratio | -0.5225 | -7.5357 | -66.875 |
| Earnings Growth Rate | 357.1429 | 250 | -65.2174 |
| Price Earnings To Growth Ratio | -0.0015 | -0.0301 | 1.0254 |
| Book Value Per Share | 0.3094 | 1.4548 | 1.7226 |
| Price To Book Ratio | 2.1617 | 1.4504 | 3.1057 |
| Ebitda | -51,455,000 | -10,837,000 | -1,735,000 |
| Enterprise Value | 56,944,700.8 | 162,063,180 | 265,366,000 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 2.6118 | 1.1731 | 0.5844 |
| Capital Expenditures | 1,424,000 | 2,852,000 | 2,088,000 |
| Free Cash Flow | 5,305,000 | -1,412,000 | 11,940,000 |
| Return On Equity | -4.1284 | -0.1958 | -0.0467 |
| One Year Beta | 2.3503 | 1.7168 | 0.1044 |
| Three Year Beta | 1.6568 | 0.943 | 0.9364 |
| Five Year Beta | 1.3771 | 0.8967 | 0.8781 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Duke John D | Director, Chief Executive Officer | 2026-03-20 | 75,000 | A | 180,000 |
| Frost Mark T | Chief Financial Officer | 2026-03-20 | 30,000 | A | 47,500 |
| Snider William | Director | 2026-03-17 | 8,475 | A | 32,000 |
| DENELSKY STEPHEN J | Director | 2026-03-17 | 10,000 | A | 21,000 |
| Snider William | Director | 2026-03-16 | 12,525 | A | 23,525 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | 2025-12-31 | 33,273 | 49,751 | 0.6688 |
| Virtu Financial LLC | 2025-12-31 | 40,000 | 59,508 | 0.6722 |
| Abel Hall, LLC | 2025-12-31 | 16,909 | 25,283 | 0.6688 |
| Point72 Asset Management, L.P. | 2025-12-31 | 9,843 | 14,717 | 0.6688 |
| CITADEL ADVISORS LLC | 2025-12-31 | 28,753 | 42,992 | 0.6688 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| GAMCO GLOBAL SERIES FUNDS, INC | 2025-12-31 | CLASS C | GMNCX | 39,000 | 26,083.2 | 0.1302 |
| GAMCO GLOBAL SERIES FUNDS, INC | 2025-12-31 | CLASS AAA | GAMNX | 39,000 | 26,083.2 | 0.1302 |
| GAMCO GLOBAL SERIES FUNDS, INC | 2025-12-31 | CLASS A | GMNAX | 39,000 | 26,083.2 | 0.1302 |
| GAMCO GLOBAL SERIES FUNDS, INC | 2025-12-31 | CLASS I | GGMMX | 39,000 | 26,083.2 | 0.1302 |
| VANGUARD INDEX FUNDS | 2025-12-31 | Institutional Select Shares | VSTSX | 1,234,707 | 825,772.04 | 0.0 |